Thursday, August 30, 2018

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH™ Nicotine Study


Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ technology to deliver nicotine as quickly as 2 minutes after oral administration. Lexaria’s technology delivered 90.2% more nicotine over the first 10 minutes of the study than the concentration-matched control formulation by the 10-minute mark. To better commercialize opportunities within the nicotine sector, the company has also completed the formation of a wholly-owned subsidiary, Lexaria Nicotine Corp. “Lexaria’s DehydraTECH™ delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever,” Lexaria Bioscience Corp CEO Chris Bunka stated in the news release. “Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”

To view the full press release, visit http://ibn.fm/hlv1J

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: